Jiangxi Synergy Pharmaceutical Co., Ltd. (SHE:300636)
China · Delayed Price · Currency is CNY 7.05
-0.16 (-2.22%)
May 21, 2026, 3:04 PM CST
SHE:300636 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 822.55 | 825.05 | 757.93 | 720.7 | 718.59 | 589.07 |
Other Revenue | 3.61 | 3.61 | 0.96 | 1.43 | 1.32 | 3.06 |
| 826.15 | 828.66 | 758.89 | 722.14 | 719.91 | 592.13 | |
Revenue Growth (YoY) | 11.74% | 9.19% | 5.09% | 0.31% | 21.58% | 35.99% |
Cost of Revenue | 637.28 | 640.88 | 539.38 | 501.78 | 493.84 | 420.85 |
Gross Profit | 188.87 | 187.78 | 219.51 | 220.36 | 226.07 | 171.28 |
Selling, General & Admin | 67.44 | 65.94 | 63.78 | 59.85 | 51.33 | 39.01 |
Research & Development | 66.37 | 64.99 | 59.45 | 63.15 | 60.91 | 39.02 |
Other Operating Expenses | 3.52 | 4.34 | 5.35 | 3.62 | 2.39 | 1.82 |
Operating Expenses | 138.59 | 136.49 | 129.84 | 126.51 | 116.11 | 81.96 |
Operating Income | 50.29 | 51.28 | 89.67 | 93.85 | 109.95 | 89.32 |
Interest Expense | -11.84 | -12.5 | -18.14 | -9.9 | -7.7 | -5.69 |
Interest & Investment Income | 25.52 | 25.52 | 30.8 | 17.58 | 2.89 | 1.97 |
Currency Exchange Gain (Loss) | 1.27 | 1.27 | 5.84 | 3.03 | -2.13 | 0.85 |
Other Non Operating Income (Expenses) | -9.43 | -0.94 | 2.16 | -0.75 | -0.75 | -0.42 |
EBT Excluding Unusual Items | 55.82 | 64.64 | 110.33 | 103.81 | 102.27 | 86.02 |
Gain (Loss) on Sale of Investments | -1.16 | -0.9 | 0.05 | - | -1.21 | 0.26 |
Gain (Loss) on Sale of Assets | -0.6 | -0.77 | -1.17 | -1.32 | -0.18 | -1.01 |
Other Unusual Items | 12.61 | 12.61 | 5.48 | 10.01 | 5.27 | 3.07 |
Pretax Income | 73.15 | 75.58 | 114.69 | 112.5 | 106.15 | 88.34 |
Income Tax Expense | 2.06 | 2.49 | 8.11 | 6.52 | 5.48 | 7.22 |
Net Income | 71.09 | 73.09 | 106.58 | 105.98 | 100.67 | 81.12 |
Net Income to Common | 71.09 | 73.09 | 106.58 | 105.98 | 100.67 | 81.12 |
Net Income Growth | -15.17% | -31.42% | 0.57% | 5.28% | 24.10% | 15.80% |
Shares Outstanding (Basic) | 420 | 420 | 420 | 380 | 326 | 309 |
Shares Outstanding (Diluted) | 420 | 420 | 420 | 380 | 346 | 338 |
Shares Change (YoY) | 0.06% | 0.03% | 10.39% | 9.89% | 2.55% | 9.05% |
EPS (Basic) | 0.17 | 0.17 | 0.25 | 0.28 | 0.31 | 0.26 |
EPS (Diluted) | 0.17 | 0.17 | 0.25 | 0.28 | 0.29 | 0.24 |
EPS Growth | -15.22% | -31.44% | -8.90% | -4.20% | 21.02% | 6.19% |
Free Cash Flow | -93.56 | -89.17 | 148.7 | -50.9 | -115.5 | -293.33 |
Free Cash Flow Per Share | -0.22 | -0.21 | 0.35 | -0.13 | -0.33 | -0.87 |
Dividend Per Share | 0.040 | 0.040 | 0.040 | 0.040 | 0.045 | 0.040 |
Dividend Growth | - | - | - | -11.11% | 12.50% | 12.99% |
Gross Margin | 22.86% | 22.66% | 28.93% | 30.51% | 31.40% | 28.93% |
Operating Margin | 6.09% | 6.19% | 11.82% | 13.00% | 15.27% | 15.09% |
Profit Margin | 8.61% | 8.82% | 14.04% | 14.68% | 13.98% | 13.70% |
Free Cash Flow Margin | -11.33% | -10.76% | 19.59% | -7.05% | -16.04% | -49.54% |
EBITDA | 184.5 | 181.44 | 203.58 | 162.39 | 175.99 | 140.34 |
EBITDA Margin | 22.33% | 21.89% | 26.83% | 22.49% | 24.45% | 23.70% |
D&A For EBITDA | 134.21 | 130.15 | 113.92 | 68.55 | 66.04 | 51.02 |
EBIT | 50.29 | 51.28 | 89.67 | 93.85 | 109.95 | 89.32 |
EBIT Margin | 6.09% | 6.19% | 11.82% | 13.00% | 15.27% | 15.09% |
Effective Tax Rate | 2.81% | 3.29% | 7.07% | 5.79% | 5.17% | 8.17% |
Revenue as Reported | 826.15 | 828.66 | 758.89 | 722.14 | 719.91 | 592.13 |
Advertising Expenses | - | 3.08 | 3.08 | 2.35 | 0.19 | 0.62 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.